Enterprise News

San Diego, CA June 30, 2010- TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis (EURONEXT: SAN and NYSE: SNY). Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.

CUPID Trial Data Presented Today as Late-Breaker at Heart Failure 2010, the Annual Meeting of the Heart Failure Association of the European Society of Cardiology. BERLIN, May 30, 2010 Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

MOUNTAIN VIEW, Calif. May 26, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), used the companys sequencing, bioinformatics and analytics services to sequence and compare a patients primary lung tumor and adjacent normal tissue. Tumor-normal pairs like this allow researchers to compare the patients genome before and after it was altered by the cancer; the patients normal genome serves as the ideal control. This is the first time that such a comparison has been made across the whole genome for a lung cancer patient. Genentechs findings will be published online in Nature later today in a paper titled The mutation spectrum revealed by paired genome sequences from a lung cancer patient.

LAJOLLA, Calif., April 28, 2010 Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that its first Phase 2 trial with MYDICAR for the treatment of advanced heart failure has met the prospectively defined safety and efficacy endpoints for the trial as defined in the Phase 2 clinical trial protocol. Study Results Demonstrate Favorable Treatment Effects with Genetically Targeted Enzyme Replacement Therapy.

Patent to Cover Use of All Adeno-Associated Viral Vectors and Routes of Administration for Delivery of SERCA2a Gene for Treatment of Heart Failure. LA JOLLA, Calif., March 23, 2010 Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the companys lead drug candidate MYDICAR, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.

It must be nice to be the CEO of a life sciences company that sells itself. When Tina Nova stepped up to the microphone at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, CA, yesterday, the Genoptix CEO was playing to a nearly full house. Investors and analysts occupied all but two or three seats, which wasnt the case in many of the other presentations given on the last day of the three-day conference (even though it drew a record total of more than 3,000 attendees, according to organizers).

Spokane, Wash.: Fuel cell provider ReliOns E-200 hydrogen fuel cell system has been named a finalist in the Green category in the CTIA Emerging Technology (E-Tech) Awards. CTIAs fifth annual E-Tech Awards program recognizes products in 15 categories in the areas of mobile consumer electronics, luxury mobile, applications, enterprise, green solutions and network technology. International CTIA WIRELESS 2010 will take place March 23-25 at the Las Vegas Convention Center.

MOUNTAIN VIEW, Calif. March 10, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that the Institute for Systems Biology (ISB) employed Complete Genomics human genome sequencing service to sequence a family quartet to determine the depth of genetic information possible in analyzing a full familys sequence, and to verify the gene responsible for Miller syndrome, a rare craniofacial disorder. Results from this collaboration will be published later today in the journal Science; the manuscript is titled Analysis of Genetic Inheritance in a Family Quartet by Whole Genome Sequencing.

Sizing Up Promising Young Firms - Venture capitalists, the investors who supply start-up money to promising young companies, are always looking for the next big thingwhether it's a hot new gadget, game or medical breakthrough. Amid a shakeout caused by poor returns, VCs are having a tough time these days, but many of them are still nurturing inventors and entrepreneurs.

There are some 10,000 privately held, venture-backed companies in the U.S. To pick the 50 of them with the greatest potential, a team from research firm VentureSource, a unit of Wall Street Journal owner News Corp., applied a strict set of standards.

MOUNTAIN VIEW, Calif. Feb. 25, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that it has been included in MIT Technology Reviews TR50, the publications 2010 list of the 50 most innovative companies in the world. The TR50 list is our selection of companies that show the most impressive innovation in commercializing new technologies, said Jason Pontin, editor in chief and publisher of Technology Review. In selecting the years top innovative companies, TR50 judges reviewed the most important inventions and breakthroughs in several categories, including biomedicine. Complete Genomics received a place on the TR50 list for its ability to provide human genome sequencing and analysis efficiently and affordably.

MOUNTAIN VIEW, Calif. Feb. 22, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today reported on its commercial success. Complete Genomics now has more than 30 customers and a strong pipeline with booked orders exceeding 500 human genomes. Its new customers, which range from academic institutions and genome centers to pharmaceutical companies, include Eli Lilly, the University of North Carolina, the Institute of Molecular Medicine at the University of Texas Health Science Center at Houston, Childrens Hospital of Philadelphia, Institute of Cancer Research UK, Academic Medical Center (AMC) University of Amsterdam, and the Department of Bioinformatics, Erasmus Medical Centre in Rotterdam, the Netherlands.